What is the estimated financial exposure or potential settlement amount for Capricor?

Based on the excerpt you provided, the press release from Kirby McInerney LLP does not disclose any figure for Capricor Therapeutics, Inc.’s (NASDAQ: CAPR) estimated financial exposure, potential settlement amount, or any range of damages that might be at issue in the securities‑fraud class action. The notice simply:

1. Reminds investors who bought Capricor securities to contact the firm (Thomas W. Elrod at [email protected]) if they wish to discuss their rights or interests in the case, and
   
2. References a “Learn More About the Class Action” link (presumably to the complaint or docket) without summarizing any monetary metrics.

Because the summary you shared contains no quantitative details about the alleged losses, the size of the class, or any projected settlement, we cannot provide an estimate of Capricor’s financial exposure from this source alone.

What you can do next

• Review the actual class‑action filing (the complaint, the docket, or the “Learn More About the Class Action” page). Those documents typically include the plaintiff’s allegations about the amount of loss per shareholder and sometimes an overall estimated damages figure.
• Monitor subsequent press releases from the law firm or the court. Law firms sometimes issue updates that disclose settlement negotiations, a “range of exposure,” or a final settlement figure once an agreement is reached.
• Check SEC filings (e.g., Form 8‑K, 10‑Q, or 10‑K) from Capricor. Companies are required to disclose material litigation that could have a “material adverse effect” on their financial condition, and they sometimes include an estimate of potential liability.

Until such additional information is publicly released, the financial exposure or potential settlement amount for Capricor remains undisclosed.